Baseret på klinisk erfaring, kan en stigning i Kaletra dosis til 533/ 133 mg to gange dagligt (∼6, 5 ml) overvejes, når det gives sammen med nevirapin, særligt til patienter, der har en sandsynlig nedsat lopinavir følsomhed.
However, based on clinical experience, Kaletra dose increase to 533/ 133 mg twice daily (~6.5 ml) may be considered when co-administered with nevirapine, particularly for patients in whom reduced lopinavir susceptibility is likely.